Warfarin in idiopathic pulmonary fibrosis: Friend or foe, is it a matter of genes and heparin?

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 2, 2013, Pages 213-214

  Tzouvelekis, Argyris ^a   Margaritopoulos, George ^a   Loukides, Stylianos ^a   Bouros, Demosthenes ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9; ERLOTINIB; FATTY ACID BINDING PROTEIN; GEFITINIB; HEPARIN; PROTEIN C; PROTEIN S; PROTHROMBIN; WARFARIN;

BLOOD CLOTTING; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; FIBROGENESIS; FIBROSING ALVEOLITIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; RESPIRATORY FAILURE; SUDDEN DEATH; TREATMENT RESPONSE;

EID: 84872542384     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/ajrccm.187.2.213     Document Type: Letter

References (9)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-1769.
3. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-1087.
4. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA; Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;186:88-95.
5. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl JMed 2012;366:1968-1977.
6. Muller-Quernheim J, Wells A. Evidence-based recommendations in idiopathic pulmonary fibrosis: a year is a long time in interstitial lung disease. Am J Respir Crit Care Med 2012;186:5-7.
7. Litin SC, Gastineau DA. Current concepts in anticoagulant therapy.Mayo Clin Proc 1995;70:266-272.
8. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, Sasaki H. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005;128:1475-1482.
9. Oldenburg J, Bevans CG, Fregin A, Geisen C, Muller-Reible C,WatzkaM. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007;98:570-578.